HMBS and acute intermittent porphyria: A prominent example of this strategy was for the treatment of acute intermittent porphyria (AIP), which is a genetic disease that can sporadically cause a host of complications ranging from loss of appetite to neurovisceral attacks.[198] The disease emerges from a lack of porphobilinogen deaminase (PBGD), leading researchers to use LNPs to deliver mRNA encoding for the missing protein.